title: Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.
abstract: Data from a multiphase schizoaffective disorder study (NCT01193153) were used to examine the effects of paliperidone palmitate once-monthly (PP1M) by subjects' illness duration, defined as recent onset (≤5 years since first psychiatric diagnosis; n = 206) and chronic illness (>5 years; n = 461). Symptom and functioning scores, as measured during open-label PP1M acute and stabilization treatment phases, improved in both subpopulations, with greater improvements in recent onset than chronic illness subjects (p ≤ 0.022). Relapse rates, examined during the double-blind, placebo-controlled phase, were higher with placebo than PP1M: 30.0% vs. 10.2% (p = 0.014; hazard ratio [HR]: 2.8; 95% confidence interval [CI]: 1.11-7.12; p = 0.029) in the recent onset subpopulation and 35.5% vs. 18.1% (p = 0.001; HR: 2.38; 95% CI: 1.37-4.12; p = 0.002) in the chronic illness subpopulation. Growing evidence in the treatment of schizophrenia and schizoaffective disorder supports early intervention with long-acting antipsychotics.
authors.affiliation: *Janssen Scientific Affairs, LLC; †Janssen Research and Development, LLC; and ‡CNS Janssen Pharmaceutical, LLC, Titusville, NJ.
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Bossie
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Turkoz
authors.forename: Larry
authors.initials: L
authors.lastname: Alphs
authors.forename: Lucy
authors.initials: L
authors.lastname: Mahalchick
authors.forename: Dong-Jing
authors.initials: DJ
authors.lastname: Fu
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D000068882:Paliperidone Palmitate / Q000008:administration & dosage / Q000494:pharmacology*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012008:Recurrence; D055502:Secondary Prevention / Q000379:methods*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D000068882:Paliperidone Palmitate